Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 16, 2024, serves as a transaction notification for the month of October 2024. The document discloses specific share acquisition activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, rather than providing general corporate financial results.
Key Financial Metrics
The filing does not contain consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for GSK plc. It exclusively reports on two individual share transactions executed on October 11, 2024, on the London Stock Exchange (XLON).
| Transaction Detail | David Redfern (President, Corporate Development) | Victoria Whyte (Company Secretary) |
|---|---|---|
| Instrument | Ordinary Shares (31 1/2 pence each) | Ordinary Shares (31 1/2 pence each) |
| Nature of Transaction | Acquisition via dividend re-investment (ISA) | Acquisition via dividend re-investment (ISA) |
| Price per Share | £14.9650 | £14.9650 |
| Volume | 20 shares | 17 shares |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. The disclosed transactions represent routine administrative acquisitions resulting from the re-investment of dividends paid on October 10, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Investor Verification Points
- Verify the dividend payment date of October 10, 2024, to confirm the timing of the re-investment.
- Confirm the market price of GSK ordinary shares on October 11, 2024, to validate the transaction price of £14.9650.
- Note that these transactions were executed within Individual Savings Accounts (ISAs), indicating personal investment vehicles rather than corporate treasury activity.